Tony Reid

Title(s)Professor Of Clinical, Medicine
SchoolHealth Sciences
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    MAGI conference on Clinical Research2013Invited Speaker
    Best of ASCO2013Invited Speaker
    American Society for Clinical Oncology2013Invited Speaker
    AACI annual conference2012Invited Speaker
    MAGI conference on Clinical Research2012Invited Speaker
    American Association for Study of Liver Disease2011Invited Speaker
    American Society of Pathology2010Invited Speaker
    Memorial Sloane Kettering Grand Rounds2010Invited Speaker
    Western Angiographic Society Meeting2010Invited Speaker
    Oncolytic Virus Conference2009Invited Speaker
    Society for Gene Therapy2007Invited Speaker
    13th International Gene Therapy Meeting2005Invited Speaker
    Best of ASCO2002Abstract presentation
    Society of Cardiology and Interventional Radiology2002Young Investigator Award
    10th International Gene Therapy Meeting2002Invited Speaker
    9th International Gene Therapy Meeting2001Invited Speaker
    American Society for Clinical Oncology1998Invited Speaker
    Barry Research1996Fellowship
    Stanford Housestaff1991Research Award
    The Interferon Society1988Young Investigator Award

    Collapse Overview 
    Collapse Overview
    Research Interests
    Professor Tony Reid’s main career goals are to develop novel therapeutic approaches to diagnose, prevent, and treat tumors with gene therapy vectors. He has focused on elucidating the underlying molecular mechanism that causes cancer, focusing primarily in gastrointestinal tumors including colorectal, pancreatic, esophageal and hepatobillary cancers. His research group conducts basic science research to study disease at the molecular level and then facilitates the translation of novel scientific discoveries into practical therapeutic applications to the clinical to benefit patients. His contributions embody the scientific approach of “bench-to-bedside” medicine, promoting greater understanding of cancer and personalized disease therapies. He has a wide range of publications on the uses of new agents for the treatment of tumors and conducts a variety of clinical trials focusing on early phase therapeutics and he also uses gene therapy strategies to enhance the immune response to these tumors. He is the lead investigator and has pioneered the use of adenoviral and vaccine vectors to the treatments of cancer and is always thinking on how he can be instrumental in developing new therapies in the laboratory and how to export them to help those suffering from cancer. His speculative nature has leaded him to explore the scientific underpinnings of cancer and to make new therapeutic options available to patients by developing new clinical trials.

    Clinical Trials: Currently there are many clinical trials on-going at the Moores Cancer Center. Professor Tony Reid’s innovative “thinking out of the box” philosophy of using highly tailored therapies for patients to directly deliver therapeutics specifically to the tumors has led to highly effective outcomes (see section b). One of the pioneering clinical trials for colon cancer patients with mainly liver metastases called the Selective Internal Radiation Therapy (SIRT) Trial using Yttrium-90 (Y-90) Radioactive Microspheres is a Phase II study. This successful clinical trial has been developed to treat patients whose disease has progressed after failing their first-line chemotherapy. Preliminary results so far have shown remarkable differences to patient health having stable disease and progression free survival (PFS) greater than thirty five months.

    b. Past findings and achievements

    i. Study Shows Liver an Excellent Target for Cancer Gene Therapy Using Viral Vectors:
    A Nature Cancer Gene Therapy paper explains the scientific research where the cancer cells in the liver are excellent targets for gene therapy using adenoviral vectors, based on a fundamental new understanding of the differences between cancerous and normal liver cells. The findings showed a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast.

    ii. Clinical Trial Evaluates Engineered Smallpox Vaccine as Potential Liver Cancer Killer: As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer.

    iii. AACI Clinical Research Initiative:

    The Right Drug for the Right Patient: Optimizing Clinical Trials Management

    iv. Spring Sprint Triathlon & Duathlon / MILLIE Award:
    Dr. Reid understands that patients undergoing anti-cancer treatments are doing their “personal best” in the fight against their disease, as are athletes doing their “personal best” as they compete in sporting events such as triathlons. This event will recognize the courage, determination, and strength that cancer patients demonstrate in their daily pursuits to achieve their personal bests.

    c. Current projects and their specific aims
    d. Our exciting new preliminary data proved that when microspheres were administered between first and second line chemotherapy to improve the lives of patients suffering from colorectal cancer. e. Title: A Phase II Study of Yttrium-90 Radioactive Resin Microspheres in the Treatment of Colorectal Adenocarcinoma Metastatic to the Liver After Failure of First-Line Combination Chemotherapy

    Specific aims:
    1) The primary objective is the assessment of progression-free survival of patients with colorectal adenocarcinoma metastatic to the liver after failure of first line combination chemotherapy with Yttrium-90 radioactive resin microspheres.
    2) Secondary objective/outcomes: The secondary objectives are the evaluation of overall survival, tumor response rates, and long-term safety of microspheres in sequence with chemotherapy.

    The Selective Internal Radiation Therapy (SIRT) Trial using Yttrium-90 (Y-90) Radioactive Microspheres inclusion and exclusion criteria can be found by following the hyperlink. We are currently enrolling patients on this trial. For further details please contact us.

    Research 2 -- Erlotinib
    a. Overall focus of the research:
    Title: A Phase I, Open-label, Dose Escalation Study of Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

    Survival of pancreatic cancer patients remains poor, and treatment with erlotinib remains one of the few agents that have demonstrated increased survival. Alternative dosing schedules for erlotinib should be explored since chronic low dose therapy fails to achieve therapeutically effective concentrations for many patients and leads to increased skin toxicity and may induce acquired resistance without significantly impacting the tumor. Therefore, higher doses given for shorter periods of exposure, similar to the dosing of most chemotherapeutic agents, may achieve more effective therapeutic doses of than chronic low dose therapy and may minimize skin toxicity observed with erlotinib.

    Current findings and achievements
    Preclinical studies performed in the laboratory of the principal investigator Professor Tony Reid support the hypothesis that the currently prescribed erlotinib dose in not optimal for achieving the most effective therapeutic dose range for pancreatic cancer as well as for minimizing skin toxicity. Therefore, our data suggests that acquired resistance can occur rapidly after exposure to erlotinib, and therefore, pulsed high-doses can help to maximize the clinical benefit of the use of erlotinib with having limited adverse effects. We have achieved to complete the first cohort in this clinical trial and we are showing some promising clinical data.
    b. Upcoming research projects
    We have many other projects in the pipeline for colon and pancreatic cancer.
    Please check the following website for further information.

    Collapse Research 
    Collapse Research Activities and Funding
    Novel TNF Chimeric Vector for Treatment of Pancreatic Cancer
    NIH/NCI R21CA122321Aug 1, 2007 - Jul 31, 2009
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Bouvet M, Reid TR, Larson C, Oronsky B, Carter C, Morris JC. Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxf Med Case Reports. 2019 Nov; 2019(11):461-463. PMID: 31844525.
      View in: PubMed
    2. Oronsky B, Reid TR, Larson C, Caroen S, Quinn M, Burbano E, Varner G, Thilagar B, Brown B, Coyle A, Ferry L, Abrouk N, Oronsky A, Scribner CL, Carter CA. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 2019 Oct; 15(30):3427-3433. PMID: 31509028.
      View in: PubMed
    3. Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter CA, Reid TR. A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). Oncoimmunology. 2018; 7(9):e1478648. PMID: 30228948.
      View in: PubMed
    4. Oronsky B, Larson C, Reid TR, Carter CA. Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer. J Investig Med High Impact Case Rep. 2018 Jan-Dec; 6:2324709618786319. PMID: 30083560.
      View in: PubMed
    5. Oronsky B, Reid TR, Oronsky A, Caroen S, Carter CA, Cabrales P. Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. Oncotarget. 2018 May 04; 9(34):23439-23442. PMID: 29805745.
      View in: PubMed
    6. Oronsky B, Ma P, Reid TR, Cabrales P, Lybeck M, Oronsky A, Oronsky N, Carter CA. Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. Neoplasia. 2018 01; 20(1):92-98. PMID: 29227909.
      View in: PubMed
    7. Oronsky B, Reid TR, Oronsky A, Carter CA. What's New in SCLC? A Review. Neoplasia. 2017 Oct; 19(10):842-847. PMID: 28888101.
      View in: PubMed
    8. Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR. No patient left behind: The promise of immune priming with epigenetic agents. Oncoimmunology. 2017; 6(10):e1315486. PMID: 29123948.
      View in: PubMed
    9. Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, Reid TR, Carter CA. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017 Nov; 80(5):895-907. PMID: 28730291.
      View in: PubMed
    10. Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B. The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury. Expert Rev Hematol. 2017 06; 10(6):575-582. PMID: 28448172.
      View in: PubMed
    11. Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P. RRx-001 protects against cisplatin-induced toxicities. J Cancer Res Clin Oncol. 2017 Sep; 143(9):1671-1677. PMID: 28417195.
      View in: PubMed
    12. Brzezniak C, Oronsky B, Trepel J, Summers TA, Cabrales P, Lee MJ, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck HE, Brown JF, Reid TR, Carter CA. RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Rep Oncol. 2017 Jan-Apr; 10(1):276-280. PMID: 28512410.
      View in: PubMed
    13. Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs. 2017 01; 26(1):109-119. PMID: 27935336.
      View in: PubMed
    14. Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA. A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001. Clin Med Insights Oncol. 2016; 10:105-108. PMID: 27840583.
      View in: PubMed
    15. Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA. Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report. Oncol Res Treat. 2016; 39(11):720-723. PMID: 27855386.
      View in: PubMed
    16. Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A. Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules. 2016 07 04; 6(3). PMID: 27384589.
      View in: PubMed
    17. Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity? Med Oncol. 2016 Jul; 33(7):63. PMID: 27229330.
      View in: PubMed
    18. Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C. Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Rep Oncol. 2016 May-Aug; 9(2):285-9. PMID: 27403127.
      View in: PubMed
    19. Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C. Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Rep Oncol. 2016 Jan-Apr; 9(1):164-70. PMID: 27065848.
      View in: PubMed
    20. Oronsky B, Carter CA, Reid TR, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P. Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance. Neoplasia. 2015 Sep; 17(9):716-722. PMID: 26476079.
      View in: PubMed
    21. Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015 Aug 21; 6(24):19976-89. PMID: 26280277.
      View in: PubMed
    22. Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA, Lao CD, Abrouk NED, Fanger GR, Infante JR. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1133-1142. PMID: 26296952.
      View in: PubMed
    23. Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR. Episensitization: Defying Time's Arrow. Front Oncol. 2015; 5:134. PMID: 26125013.
      View in: PubMed
    24. Hecht JR, Reid TR, Garrett CR, Beck JT, Davidson SJ, Mackenzie MJ, Brandt U, Rizvi S, Sharma S. Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer. Anticancer Res. 2015 Mar; 35(3):1567-73. PMID: 25750312.
      View in: PubMed
    25. Mendez N, Herrera V, Zhang L, Hedjran F, Feuer R, Blair SL, Trogler WC, Reid TR, Kummel AC. Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency. Biomaterials. 2014 Nov; 35(35):9554-61. PMID: 25154663.
      View in: PubMed
    26. Sze DY, Reid TR, Rose SC. Oncolytic virotherapy. J Vasc Interv Radiol. 2013 Aug; 24(8):1115-22. PMID: 23885911.
      View in: PubMed
    27. Larson C, Mendez N, Reid T. Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system. Mol Ther. 2013 May; 21(5):922-3. PMID: 23636291.
      View in: PubMed
    28. Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, Rado TA, McGee PJ, Richards DA, Tarazi J, Rosbrook B, Kim S, Cartwright TH. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer. 2013 07 15; 119(14):2555-63. PMID: 23605883.
      View in: PubMed
    29. Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography. Hum Gene Ther. 2012 Jan; 23(1):91-7. PMID: 21895536.
      View in: PubMed
    30. Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, Tawfik H. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010 Sep; 21(9):1119-28. PMID: 20486770.
      View in: PubMed
    31. Costantini CL, Reid TR, Bouvet M. Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer. Hepatogastroenterology. 2009 May-Jun; 56(91-92):645-9. PMID: 19621672.
      View in: PubMed
    32. Reid T. Fighting fire with fire: effects of oncolytic virotherapy on underlying viral hepatitis in hepatocellular carcinoma. Mol Ther. 2008 Sep; 16(9):1521-3. PMID: 18725877.
      View in: PubMed
    33. Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol. 2008 Aug; 4(4):483-500. PMID: 18684060.
      View in: PubMed
    34. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther. 2008 Aug; 10(4):371-9. PMID: 18683102.
      View in: PubMed
    35. Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol. 2007 Aug 10; 25(23):3544-6. PMID: 17687160.
      View in: PubMed
    36. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005 Aug; 12(8):673-81. PMID: 15803147.
      View in: PubMed
    37. Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M, Ahrar K, Gupta S, Reid TR. Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol. 2003 Mar; 14(3):279-90. PMID: 12631632.
      View in: PubMed
    38. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003 Feb; 9(2):555-61. PMID: 12576418.
      View in: PubMed
    39. Reid TR, Sze DY. Developments in medical oncology and their implications for interventional radiology. Tech Vasc Interv Radiol. 2002 Sep; 5(3):177-81. PMID: 12524649.
      View in: PubMed
    40. Milkes DE, Friedland S, Lin OS, Reid TR, Soetikno RM. A novel method to control severe upper GI bleeding from metastatic cancer with a hemostatic sealant: the CoStasis surgical hemostat. Gastrointest Endosc. 2002 May; 55(6):735-40. PMID: 11979262.
      View in: PubMed